CAD
$1000,395,000
CannTrust
BOUGHT DEAL, JUNE 2018
The mergers and acquisitions advisory capability at Bloom Burton guides clients to conceptualize, structure and execute transactions to maximize returns and company performance.
Our team’s professional expertise in healthcare and intellectual property also allows us to guide our clients with scientific and technical due diligence on their M&A opportunities and development strategies.
For more information on our M&A services, please contact:
Jolyon Burton
jburton@bloomburton.com
416-640-7585
<
>
CAD
$1000,395,000
CannTrust
BOUGHT DEAL, JUNE 2018
<
>
US $2,400,000,000*
Fusion Pharmaceuticals
M&A Advisory
JUNE 2024
*Up to
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation RCs. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical-stage development portfolio includes lead program, FPI-2265, targeting PSMA for mCRPC and novel RCs targeting solid tumors. Fusion has a fully operational Good Manufacturing Practice compliant state-of-the-art radiopharmaceutical manufacturing facility to meet supply demand for Fusion's growing pipeline of radioconjugates.
Fusion Pharmaceuticals
Searchlight Pharma Inc.
M&A Advisory
APRIL 2024
About Searchlight
Searchlight Pharma Inc., headquartered in Montreal, is a leading Canadian-based specialty healthcare company that executes best-in-class search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products. Searchlight's core promoted products focus on women's health, dermatology, allergy, pain management and hospital specialty markets, and its team is committed to improving people's lives by bringing the right products to market.
Searchlight Pharma Inc.
US $1,075,000,000
Inversago Pharma
Financial Advisor
SEPTEMBER 2023
Based in Montreal Canada, Inversago Pharma, is a privately owned, clinical stage company, and leader in the development of next generation CB1 receptor blocker therapies designed to help patients with complications associated with metabolic and fibrotic diseases. Inversago aims to provide new treatment options that improve the lives of patients affected by a wide range of cardiometabolic disorders.
Inversago Pharma
Juno Pharmaceuticals Canada
MERGER & ACQUISTION ADVISORY, DEBT FINANCING
MAY 2023
Juno Pharmaceuticals Canada specializes in manufacturing, developing, and delivering high-quality, cost-effective, complex, and high value generic, branded and biosimilar products. With operations in Toronto and Montreal, Juno is one of the largest generic injectable businesses in Canada with domestic manufacturing capabilities and a robust distribution pipeline throughout 22 international markets. An early member of the global Juno Pharmaceuticals group, Juno’s global operations span four continents and consist of over 14 diverse pharmaceutical and medical device businesses spread across Canada, the United Kingdom, the European Union, Australia, and South Africa.
Juno Pharmaceuticals Canada
CDN $85,000,000*
Miravo Healthcare
MERGER & ACQUISTION ADVISORY
MARCH 2023
*Enterprise Value
Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada, though the Company is in the process of winding-down its manufacturing operations in Varennes.
Miravo Healthcare
CDN $27,200,000
Mimi's Rock Corp.
MERGER & ACQUISTION ADVISORY
FEBRUARY 2023
Mimi's Rock Corp. is an online dietary supplement and wellness company which market and sells its products under the Dr. Tobias, All Natural Advice and Maritime Naturals brand names. The Dr. Tobias brand features over 30 products, including the top-selling Colon 14-Day Cleanse and the #1 selling Omega 3 Fish Oil on Amazon.com. All Natural Advice and Maritime Naturals products focus on skin and beauty care. Products sold under the All Natural and Maritime Naturals brand names are made in Canada and registered with Health Canada and under the EU Cosmetics Act. All Natural Advice has been featured on BNN as a top selling skincare brand in Canada, and has been rated the #1 Beauty Brand on Amazon Canada for the past four years.
Mimi's Rock Corp.
RxPx
MERGER & ACQUISTION ADVISORY
SEPTEMBER 2022
About RxPx Corp.
In the evolving digital health industry, a newly merged company is on a mission to help healthcare and transform lives. RxMx and Curatio, backed by private equity firm Pemba Capital Partners, have merged to form RxPx.
RxPx is positioned to become the global leader in patient management software for life sciences companies globally. The combined strengths of newly merged RxMx and Curatio will deliver next level solutions to transform the lives of patients, especially those on specialty therapies.
The name RxPx combines Rx for prescription medication and Px for patient experience. With a mission of No Patient Alone, RxPx provides an end to end workflow solution that reduces burden on doctors, and supports patients at scale. The merger comes at a time when health systems are collapsing, pharmaceutical companies are undergoing massive change, and patients are increasingly relying on digital options.
RxPx is used in over 100 countries, available in 15 languages and has been designed specifically for the privacy, security and compliance needs of healthcare. RxMx was started by doctors for doctors to support physician workflows through automated processes that increase speed and access to therapy. Curatio was started by patients for patients as a social health prescription, enabling any healthcare organization to easily deliver private, personalized social support, education, daily coaching and adherence tracking
RxPx
Field Trip Health Ltd.
SPIN-OUT; MERGER & ACQUISTION ADVISORY
AUGUST 2022
About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
About Field Trip Health & Wellness Ltd.
Field Trip Health & Wellness Ltd. is a global leader in psychedelic therapies. With health centres across North America and Europe, along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.
Field Trip Health Ltd.
Undisclosed Digital Health Company
Advisory
JUNE 2022
Undisclosed Digital Health Company
Pillar5 Pharma Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2022
Pillar5, based in Arnprior, Ontario, became in independent company in 2009 and is one of the primary North American CDMOs for the production of sterile ophthalmic solutions and for solid dose manufacturing (tablets, capsules, etc.). Pillar5 was the first CDMO to offer multi-dose preservative free manufacturing capabilities for the North American ophthalmic market and offers services ranging from formulation, product manufacturing and custom packaging to technical services.
For information: www.pillar5pharma.com.
Pillar5 Pharma Inc.
Searchlight Pharma
MERGER & ACQUISTION ADVISORY, DEBT FINANCING
JANUARY 2022
MONTRÉAL, Jan. 5, 2022 /CNW Telbec/ - Searchlight Pharma Inc. ("Searchlight"), a Canada focused, Montréal-based specialty healthcare company focused on women's health, urogynecology, and urology, announced today that it has completed the acquisition of ERFA Canada 2012 Inc. ("ERFA"), a Montréal-based distributor of niche pharmaceutical products across Canada addressing a range of underserved medical indications.
"We are very excited to announce the acquisition of ERFA and to welcome their high performing team to the Searchlight family," said Mark Nawacki, President & CEO of Searchlight Pharma Inc. "ERFA's portfolio of 23 marketed brands is synergistic with our existing business, and we look forward to continuing ERFA's mission to provide access to important niche products to patients across the country. The combination of Searchlight and ERFA creates a compelling platform with attractive critical mass across products, business operations and infrastructure. We are very well positioned to continue to deliver on our growth strategy while providing dependability and value to Canadian customers and patients."
Searchlight was advised by Bloom Burton Securities Inc. (financial advisory), Ernst & Young LLP (strategy and transactions, tax advisory), and Davies Ward Phillips and Vineberg (legal advisory). ERFA was advised by PricewaterhouseCoopers Corporate Finance Inc. (financial advisory), Raymond Chabot Grant Thornton LLP and Deloitte LLP (tax advisory), and Dunton Rainville (legal advisory).
Details of the transaction were not disclosed.
Searchlight Pharma
CDN$7,250,000
Satellos Bioscience
PRIVATE PLACEMENT
APRIL 2021
iCo Therapeutics Inc. (TSXV: ICO) (OTC: ICOTF) ("iCo" or the "Company") is pleased to announce that it has closed its previously announced private placement (the "Financing") in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act. The completion of the Arrangement will result in the reverse takeover of the Company as defined in the policies of the TSX Venture Exchange ("TSXV") and the resulting entity will continue to operate in the life sciences industry under the name "Satellos Bioscience Inc." (the "Resulting Issuer").
Pursuant to the Financing, the Company issued 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million. Each Subscription Receipt will entitle the holder thereof to receive, upon satisfaction of certain escrow release conditions, including without limitation, the completion of the Arrangement, and without payment of additional consideration, one common share of the Resulting Issuer (a "Resulting Issuer Share"). The proceeds from the Financing have been placed in escrow and, upon satisfaction of the escrow release conditions, will be used for research, development, and general corporate expenses of the Resulting Issuer.
The Resulting Issuer Shares issued in connection with the Financing will be subject to a hold period expiring 4 months and one day from the date of issuance in accordance with applicable Canadian securities laws. Additionally, in connection with the Financing, certain Resulting Issuer Shares issued to former shareholders of Satellos pursuant to the Arrangement will be subject to a lock-up agreement.
The Financing was led by Bloom Burton Securities Inc. and includes Richardson Wealth Ltd.
Satellos Bioscience
CDN$56,000,000
adMare BioInnovations
MERGER & ACQUISTION ADVISORY
MARCH 2020
adMare BioInnovations
US$178,000,000
Dahlin Pharma
MERGER & ACQUISTION ADVISORY
DECEMBER 2019
Acquisition of Seroquel XR by Dahlin Pharma and Cheplapharm.
Bloom Burton Securities Inc. acted as advisor to Dahlin Pharma.
Dahlin Pharma
US$110,000,000
Nuvo Pharmaceuticals Inc.
MERGER & ACQUISTION ADVISORY
DECEMBER 2018
Nuvo Pharmaceuticals Inc.
UP TO CDN$88,000,000
Pediapharm Inc.
Merger & Acquisition Advisory
OCTOBER 2018
Pediapharm Inc.
Precision Nutrition
MERGER & ACQUISTION ADVISORY
DECEMBER 2017
Precision Nutrition
EUR €13,900,000
Hamilton Thorne Ltd.
MERGER & ACQUISTION ADVISORY
APRIL 2017
Hamilton Thorne Ltd.
US $10,250,000
LED Medical Diagnostics Inc.
MERGER & ACQUISITION ADVISORY
FEBRUARY 2017
LED Medical Diagnostics Inc.
CAD $6,000,000
Red Leaf Medical Inc.
MERGER & ACQUISITION ADVISORY
SEPTEMBER 2016
Red Leaf Medical Inc.
Response Biomedical Corp.
MERGER & ACQUISITION ADVISORY
AUGUST 2016
Response Biomedical Corp.
Noden Pharma Inc.
MERGER & ACQUISITION ADVISORY
JULY 2016
Noden Pharma Inc.
US $148,000,000
Tribute Pharmaceuticals Canada Inc.
Merger & Acquisition Advisory
FEBRUARY 2016
Tribute Pharmaceuticals Canada Inc.
Canadian Public Biotech Company
MERGER & ACQUISITION ADVISORY
JANUARY 2016
Canadian Public Biotech Company
CAD $47,000,000
Alveda Pharmaceuticals Inc.
Merger & Acquisition Advisory
NOVEMBER 2015
Alveda Pharmaceuticals Inc.
CAD $25,000,000
Medical Futures Inc.
Merger & Acquisition Advisory
JUNE 2015
Medical Futures Inc.
US $73,200,000
CRH Medical Corporation
Merger & Acquisition Advisory
DECEMBER 2014
CRH Medical Corporation
US $45,000,000
Nuvo Research Inc.
Merger & Acquisition Advisory
OCTOBER 2014
Nuvo Research Inc.
Warnex Inc.
MERGER & ACQUISITION ADVISORY
MAY 2014
Warnex Inc.
Bioniche Life Sciences Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2014
Bioniche Life Sciences Inc.
CAD $7,530,000
Triton Pharma Inc.
Mergers & Acquisition Advisory
JANUARY 2014
Triton Pharma Inc.
Approx. CAD $357,000,000
Medicago Inc.
MERGER & ACQUISITION ADVISORY
SEPTEMBER 2013
Medicago Inc.
Approx. CAD $13,000,000
Thallion Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
August 2013
Thallion Pharmaceuticals Inc.
Victhom Human Bionics Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2013
Victhom Human Bionics Inc.
Approx. US 510,000,000
YM BioSciences Inc.
MERGER & ACQUISITION ADVISORY
DECEMBER 2012
YM BioSciences Inc.
Warnex Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2012
Warnex Inc.
Pharmagap Inc.
MERGER & ACQUISITION ADVISORY
JULY 2012
Pharmagap Inc.
Approx. CAD $10,000,000
Stellar Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
DECEMBER 2011
Stellar Pharmaceuticals Inc.
Advitech Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2011
Advitech Inc.
Miraculins Inc.
MERGER & ACQUISITION ADVISORY
AUGUST 2010
Miraculins Inc.
Patient Home Monitoring Corp.
MERGER & ACQUISITION ADVISORY
JUNE 2010
Patient Home Monitoring Corp.
Approx. CAD $7,000,000
DiaMedica Inc.
MERGER & ACQUISITION ADVISORY
JUNE 2010
DiaMedica Inc.
Conjuchem LLC
MERGER & ACQUISITION ADVISORY
MARCH 2010
Conjuchem LLC
Approx. CAD $12,500,000
YM Biosciences Inc.
MERGER & ACQUISITION ADVISORY
FEBRUARY 2010
YM Biosciences Inc.
Medicure Inc.
MERGER & ACQUISITION ADVISORY
JANUARY 2010
Medicure Inc.
Bradmer Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
JULY 2009
Bradmer Pharmaceuticals Inc.
Med BioGene Inc.
MERGER & ACQUISITION ADVISORY
June 2009
Med BioGene Inc.